Whalesbook
### Price Controls Struggle Against Soaring Costs
India's pharmaceutical industry is pushing the government for relief as a strict annual price revision for essential medicines limits increases to just 0.6%. This small adjustment, linked to the Wholesale Price Index (WPI), fails to keep pace with the rising costs of raw materials and intermediates, fueled by global events. The policy affects about 1,000 drugs on the National List of Essential Medicines (NLEM). Industry groups consider the current situation "hardly anything to cheer for," highlighting how inadequate the revision is to cover higher expenses.
### Input Costs Surge, Margins Shrink
Global conflicts are creating significant cost inflation across the pharmaceutical supply chain. Key ingredients like glycerine and propylene glycol, along with various solvents, are now much more expensive. Prices for vital Active Pharmaceutical Ingredients (APIs) and intermediates have also jumped sharply, with some API costs rising by 15% to 130% in the last year. These higher expenses, combined with increased freight and energy costs, are cutting into operating profits. Industry projections show a decline in profitability by 200 to 250 basis points in recent financial years.
### Industry Seeks Price Flexibility
Pharmaceutical industry groups are planning to ask the government for changes, potentially including exemptions from the Wholesale Price Index (WPI) pricing rule for essential medicines. They argue that the current rules, meant for stable times, are not working in today's unpredictable economy. Previous price increases, like 12% in 2023 and 10% in 2022, were needed due to earlier cost rises, showing a growing gap between what companies face and what policies allow. The industry wants a larger price increase to maintain operations and innovation. They note that non-essential drugs can have prices rise up to 10% annually, while essential NLEM drugs are locked into restrictive WPI-linked changes.
### Supply Chain Risks and Global Outlook
The industry also faces potential disruptions in its supply chain, such as a shortage of propane affecting the production of vitamins and hormones. These wider vulnerabilities highlight how sensitive India's pharmaceutical manufacturing system is. Analysts expect the Indian pharma sector's revenue to grow between 7-9% in FY2026, thanks to domestic demand and exports to Europe. However, the U.S. market remains difficult due to falling prices and regulatory checks. If current pricing policies stay the same, it could worsen profit pressures. This could impact the industry's ability to invest in research and development (R&D) and its global role as the "pharmacy of the world."
### Stagnation Risk Under Rigid Pricing
Sticking strictly to WPI-based price adjustments for essential medicines, while global input costs are climbing, puts Indian drugmakers at a major disadvantage. Many countries are dealing with inflation and looking for flexible pricing, but India's policy seems outdated. This rigidity particularly affects smaller companies and those making NLEM drugs. It could lead to less production, market consolidation, or a shift towards more profitable, non-essential products. The risk is reduced investment in R&D and weakened long-term operations, as companies rely on short-term cost cuts. Added to this are regulatory challenges in export markets like the U.S. and potential trade policy changes, making it tough for Indian firms to compete globally without sufficient domestic margin support.